Short Interest in Kezar Life Sciences, Inc. (NASDAQ:KZR) Decreases By 10.7%

Kezar Life Sciences, Inc. (NASDAQ:KZR) was the recipient of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 2,850,000 shares, a decrease of 10.7% from the June 15th total of 3,190,000 shares. Based on an average trading volume of 713,800 shares, the days-to-cover ratio is currently 4.0 days.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Fidelis Capital Partners LLC acquired a new position in shares of Kezar Life Sciences in the 1st quarter worth $25,000. SG Americas Securities LLC lifted its stake in Kezar Life Sciences by 33.8% during the fourth quarter. SG Americas Securities LLC now owns 43,950 shares of the company’s stock valued at $42,000 after buying an additional 11,109 shares in the last quarter. Panagora Asset Management Inc. acquired a new position in shares of Kezar Life Sciences in the fourth quarter worth about $80,000. Marquette Asset Management LLC purchased a new position in shares of Kezar Life Sciences in the first quarter worth approximately $114,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Kezar Life Sciences by 35.4% in the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after acquiring an additional 71,543 shares in the last quarter. 67.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Kezar Life Sciences in a research report on Friday, May 10th.

Kezar Life Sciences Stock Performance

KZR stock traded up $0.02 during trading on Wednesday, reaching $0.67. 2,302 shares of the company’s stock were exchanged, compared to its average volume of 706,591. Kezar Life Sciences has a 1-year low of $0.54 and a 1-year high of $2.55. The firm has a market cap of $49.03 million, a PE ratio of -0.48 and a beta of 0.28. The company’s fifty day moving average price is $0.68 and its 200-day moving average price is $0.81. The company has a quick ratio of 11.49, a current ratio of 11.48 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. On average, research analysts expect that Kezar Life Sciences will post -1.24 EPS for the current fiscal year.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.